Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03645993 · ClinicalTrials.gov registry record
Early Onset Alzheimer's Disease Genomic Study
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 26
- Enrollment target
NCT03645993: Completed study, sponsored by Baylor Research Institute.
NCT03645993 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03645993 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your DNA and RNA in order to help doctors diagnose, treat, and monitor people at risk of developing Early-Onset AD in the future.
Primary Outcome
Blood will be taken so that tests can be run to locate a biomarker that will help to diagnose and treat early-onset Alzheimer's disease.
Interventions
- GENETIC Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-06-16 |
| Est. Completion | 2024-04-24 |
What the finished NCT03645993 record still lists
NCT03645993 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Genetic Testing is the first listed.
NCT03645993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03645993 about?
NCT03645993 is a clinical study titled "Early Onset Alzheimer's Disease Genomic Study". The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researche...
What is the current status of trial NCT03645993?
This trial is currently completed. The enrollment target is 26 participants. The study started on 2017-06-16. Estimated completion is 2024-04-24.
What interventions are being tested in trial NCT03645993?
The interventions under investigation include: Genetic Testing (GENETIC).
Who is sponsoring clinical trial NCT03645993?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI